{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T18:58:33Z","timestamp":1783623513163,"version":"3.55.0"},"reference-count":67,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,5,1]],"date-time":"2026-05-01T00:00:00Z","timestamp":1777593600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T00:00:00Z","timestamp":1778025600000},"content-version":"vor","delay-in-days":5,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Alma Mater Studiorum - Universit\u00e0 di Bologna"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Targ Oncol"],"published-print":{"date-parts":[[2026,5]]},"DOI":"10.1007\/s11523-026-01222-3","type":"journal-article","created":{"date-parts":[[2026,5,6]],"date-time":"2026-05-06T14:16:29Z","timestamp":1778076989000},"page":"433-445","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Posterior Reversible Encephalopathy Syndrome with Angiogenesis Inhibitors for Solid Tumours: Clues from a Disproportionality Analysis of the FDA Adverse Event Reporting System and Pharmacodynamics"],"prefix":"10.1007","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0009-0009-6902-6843","authenticated-orcid":false,"given":"Monia","family":"Donati","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Cancellerini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentina","family":"Giunchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simone","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Massari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Gelsomino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Poluzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emanuel","family":"Raschi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,6]]},"reference":[{"key":"1222_CR1","doi-asserted-by":"publisher","first-page":"a006577","DOI":"10.1101\/cshperspect.a006577","volume":"2","author":"KL Meadows","year":"2012","unstructured":"Meadows KL, Hurwitz HI. Anti-VEGF therapies in the clinic. Cold Spring Harb Perspect Med. 2012;2:a006577\u2013a006577. https:\/\/doi.org\/10.1101\/cshperspect.a006577.","journal-title":"Cold Spring Harb Perspect Med"},{"key":"1222_CR2","doi-asserted-by":"publisher","first-page":"107059","DOI":"10.1016\/j.phrs.2024.107059","volume":"200","author":"R Roskoski","year":"2024","unstructured":"Roskoski R. Properties of FDA-approved small molecule protein kinase inhibitors: a 2024 update. Pharmacol Res. 2024;200:107059. https:\/\/doi.org\/10.1016\/j.phrs.2024.107059.","journal-title":"Pharmacol Res"},{"key":"1222_CR3","doi-asserted-by":"publisher","first-page":"9926","DOI":"10.3390\/ijms22189926","volume":"22","author":"E Ioannidou","year":"2021","unstructured":"Ioannidou E, Moschetta M, Shah S, Parker JS, Ozturk MA, Pappas-Gogos G, et al. Angiogenesis and anti-angiogenic treatment in prostate cancer: mechanisms of action and molecular targets. Int J Mol Sci. 2021;22:9926. https:\/\/doi.org\/10.3390\/ijms22189926.","journal-title":"Int J Mol Sci"},{"key":"1222_CR4","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1038\/nrd.2015.17","volume":"15","author":"N Ferrara","year":"2016","unstructured":"Ferrara N, Adamis AP. Ten years of anti-vascular endothelial growth factor therapy. Nat Rev Drug Discov. 2016;15:385\u2013403. https:\/\/doi.org\/10.1038\/nrd.2015.17.","journal-title":"Nat Rev Drug Discov"},{"key":"1222_CR5","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1016\/j.tcm.2012.09.008","volume":"23","author":"SM Bair","year":"2013","unstructured":"Bair SM, Choueiri TK, Moslehi J. Cardiovascular complications associated with novel angiogenesis inhibitors: emerging evidence and evolving perspectives. Trends Cardiovasc Med. 2013;23:104\u201313. https:\/\/doi.org\/10.1016\/j.tcm.2012.09.008.","journal-title":"Trends Cardiovasc Med"},{"key":"1222_CR6","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1016\/j.cjca.2014.02.011","volume":"30","author":"HY Small","year":"2014","unstructured":"Small HY, Montezano AC, Rios FJ, Savoia C, Touyz RM. Hypertension due to antiangiogenic cancer therapy with vascular endothelial growth factor inhibitors: understanding and managing a new syndrome. Can J Cardiol. 2014;30:534\u201343. https:\/\/doi.org\/10.1016\/j.cjca.2014.02.011.","journal-title":"Can J Cardiol"},{"key":"1222_CR7","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.ejca.2016.07.008","volume":"66","author":"C Tlemsani","year":"2016","unstructured":"Tlemsani C, Mir O, Psimaras D, Vano Y-A, Ducreux M, Escudier B, et al. Acute neurovascular events in cancer patients receiving anti-vascular endothelial growth factor agents: clinical experience in Paris University Hospitals. Eur J Cancer. 2016;66:75\u201382. https:\/\/doi.org\/10.1016\/j.ejca.2016.07.008.","journal-title":"Eur J Cancer"},{"key":"1222_CR8","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1007\/s00415-022-11450-y","volume":"270","author":"A Balcerac","year":"2023","unstructured":"Balcerac A, Bihan K, Psimaras D, Lebrun-Vignes B, Salem J-E, Weiss N. Drugs associated with posterior reversible encephalopathy syndrome, a worldwide signal detection study. J Neurol. 2023;270:975\u201385. https:\/\/doi.org\/10.1007\/s00415-022-11450-y.","journal-title":"J Neurol"},{"key":"1222_CR9","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1080\/14740338.2024.2327510","volume":"23","author":"C-L Lei","year":"2024","unstructured":"Lei C-L, Gui X-L, Wang L-Y, Guo Y-J, Li Y. Analysis of drug-induced posterior reversible encephalopathy syndrome using the Food and Drug Administration adverse drug events reporting system database. Expert Opin Drug Saf. 2024;23:607\u201316. https:\/\/doi.org\/10.1080\/14740338.2024.2327510.","journal-title":"Expert Opin Drug Saf"},{"key":"1222_CR10","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1007\/s11523-011-0201-x","volume":"6","author":"C Tlemsani","year":"2011","unstructured":"Tlemsani C, Mir O, Boudou-Rouquette P, Huillard O, Maley K, Ropert S, et al. Posterior reversible encephalopathy syndrome induced by anti-VEGF agents. Targ Oncol. 2011;6:253\u20138. https:\/\/doi.org\/10.1007\/s11523-011-0201-x.","journal-title":"Targ Oncol"},{"issue":"15","key":"1222_CR11","doi-asserted-by":"publisher","first-page":"e1554","DOI":"10.1212\/WNL.0000000000207604","volume":"101","author":"FO Otite","year":"2023","unstructured":"Otite FO, Patel SD, Anikpezie N, Hoffman H, Beutler T, Akano EO, et al. Demographic disparities in the incidence, clinical characteristics, and outcome of posterior reversible encephalopathy syndrome in the United States. Neurology. 2023;101(15):e1554\u20139. https:\/\/doi.org\/10.1212\/WNL.0000000000207604.","journal-title":"Neurology"},{"key":"1222_CR12","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1136\/practneurol-2021-003194","volume":"22","author":"JD Triplett","year":"2022","unstructured":"Triplett JD, Kutlubaev MA, Kermode AG, Hardy T. Posterior reversible encephalopathy syndrome (PRES): diagnosis and management. Pract Neurol. 2022;22:183\u20139. https:\/\/doi.org\/10.1136\/practneurol-2021-003194.","journal-title":"Pract Neurol"},{"key":"1222_CR13","doi-asserted-by":"publisher","first-page":"806","DOI":"10.1177\/1078155215611048","volume":"22","author":"MK Ery\u0131lmaz","year":"2016","unstructured":"Ery\u0131lmaz MK, Mutlu H, Salim DK, Musri FY, Co\u015fkun H\u015e. Fatal posterior revesible leukoencephalopathy syndrome associated coma induced by bevacizumab in metastatic colorectal cancer and review of literature. J Oncol Pharm Pract. 2016;22:806\u201310. https:\/\/doi.org\/10.1177\/1078155215611048.","journal-title":"J Oncol Pharm Pract"},{"key":"1222_CR14","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1016\/j.jocn.2017.01.005","volume":"40","author":"J Massey","year":"2017","unstructured":"Massey J. Posterior reversible encephalopathy syndrome (PRES) with sub-arachnoid haemorrhage after bevacizumab and 5-FU. J Clin Neurosci. 2017;40:57\u20139. https:\/\/doi.org\/10.1016\/j.jocn.2017.01.005.","journal-title":"J Clin Neurosci"},{"key":"1222_CR15","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1080\/20009666.2018.1478563","volume":"8","author":"M Hamid","year":"2018","unstructured":"Hamid M, Ghani A, Micaily I, Sarwar U, Lashari B, Malik F. Posterior reversible encephalopathy syndrome (PRES) after bevacizumab therapy for metastatic colorectal cancer. J Community Hosp Intern Med Perspect. 2018;8:130\u20133. https:\/\/doi.org\/10.1080\/20009666.2018.1478563.","journal-title":"J Community Hosp Intern Med Perspect"},{"key":"1222_CR16","doi-asserted-by":"publisher","first-page":"2050313X2311764","DOI":"10.1177\/2050313X231176401","volume":"11","author":"A Liapi","year":"2023","unstructured":"Liapi A, Atat C, Dunet V, Sarivalasis A. Dual first-line maintenance by PARP inhibitor and bevacizumab can cause confusion in high-grade serous ovarian cancer: a case of PRES and a review of the literature. SAGE Open Med Case Rep. 2023;11:2050313X231176401. https:\/\/doi.org\/10.1177\/2050313X231176401.","journal-title":"SAGE Open Med Case Rep"},{"issue":"23","key":"1222_CR17","doi-asserted-by":"publisher","first-page":"3559","DOI":"10.1200\/JCO.2007.12.8710","volume":"25","author":"G Mart\u00edn","year":"2007","unstructured":"Mart\u00edn G, Bellido L, Cruz JJ. Reversible posterior leukoencephalopathy syndrome induced by sunitinib. J Clin Oncol. 2007;25(23):3559. https:\/\/doi.org\/10.1200\/JCO.2007.12.8710.","journal-title":"J Clin Oncol"},{"key":"1222_CR18","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1155\/2014\/952624","volume":"2014","author":"R Costa","year":"2014","unstructured":"Costa R, Costa R, Costa R, Junior GMDB, Cartaxo HQ, De Barros AC. Reversible posterior encephalopathy syndrome secondary to sunitinib. Case Rep Oncol Med. 2014;2014:1\u20133. https:\/\/doi.org\/10.1155\/2014\/952624.","journal-title":"Case Rep Oncol Med"},{"key":"1222_CR19","doi-asserted-by":"publisher","first-page":"995","DOI":"10.1007\/s13760-020-01367-6","volume":"120","author":"N Rifino","year":"2020","unstructured":"Rifino N, Mantero V, Filizzolo MG, Basilico P, Scaccabarozzi C, Arnoffi J, et al. Sunitinib associated posterior reversible encephalopathy syndrome in a patient treated for GIST. Acta Neurol Belg. 2020;120:995\u20137. https:\/\/doi.org\/10.1007\/s13760-020-01367-6.","journal-title":"Acta Neurol Belg"},{"key":"1222_CR20","doi-asserted-by":"publisher","first-page":"1964","DOI":"10.1016\/j.asjsur.2022.04.034","volume":"45","author":"X Liu","year":"2022","unstructured":"Liu X, Hong W, Wang L, Zhang Z. Sunitinib-associated posterior reversible encephalopathy syndrome in a patient with a gastrointestinal stromal tumor. Asian J Surg. 2022;45:1964\u20135. https:\/\/doi.org\/10.1016\/j.asjsur.2022.04.034.","journal-title":"Asian J Surg"},{"key":"1222_CR21","doi-asserted-by":"publisher","first-page":"1436","DOI":"10.1007\/s12032-009-9378-6","volume":"27","author":"E Dogan","year":"2010","unstructured":"Dogan E, Aksoy S, Arslan C, Dede DS, Altundag K. Probable sorafenib-induced reversible encephalopathy in a patient with hepatocellular carcinoma. Med Oncol. 2010;27:1436\u20137. https:\/\/doi.org\/10.1007\/s12032-009-9378-6.","journal-title":"Med Oncol"},{"issue":"2","key":"1222_CR22","doi-asserted-by":"publisher","first-page":"281","DOI":"10.3892\/mco.2017.1291","volume":"7","author":"N Furubayashi","year":"2017","unstructured":"Furubayashi N, Negishi T, Iwai H, Nagase K, Nakamura M. Sorafenib-induced reversible posterior leukoencephalopathy in patients with renal cell carcinoma: a report of two cases. Mol Clin Oncol. 2017;7(2):281\u20134. https:\/\/doi.org\/10.3892\/mco.2017.1291.","journal-title":"Mol Clin Oncol"},{"key":"1222_CR23","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1159\/000443970","volume":"100","author":"M Laruelle","year":"2018","unstructured":"Laruelle M, Filleul B, Duprez T, Machiels J-P. Posterior reversible encephalopathy syndrome associated with Sorafenib and successful retreatment. Urol Int. 2018;100:357\u201360. https:\/\/doi.org\/10.1159\/000443970.","journal-title":"Urol Int"},{"key":"1222_CR24","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1007\/s10637-017-0521-5","volume":"36","author":"S Deguchi","year":"2018","unstructured":"Deguchi S, Mitsuya K, Nakasu Y, Hayashi N, Katagiri H, Murata H, et al. Posterior reversible encephalopathy syndrome (PRES) induced by pazopanib, a multi-targeting tyrosine kinase inhibitor, in a patient with soft-tissue sarcoma: case report and review of the literature. Investig New Drugs. 2018;36:346\u20139. https:\/\/doi.org\/10.1007\/s10637-017-0521-5.","journal-title":"Investig New Drugs"},{"key":"1222_CR25","doi-asserted-by":"publisher","first-page":"223","DOI":"10.1111\/jcpt.13261","volume":"46","author":"T Tatsumichi","year":"2021","unstructured":"Tatsumichi T, Tanaka H, Okazaki T, Takahashi K, Suzuki K, Kawakita K, et al. Uterine sarcoma with posterior reversible encephalopathy syndrome associated with pazopanib. J Clin Pharm Ther. 2021;46:223\u20136. https:\/\/doi.org\/10.1111\/jcpt.13261.","journal-title":"J Clin Pharm Ther"},{"key":"1222_CR26","doi-asserted-by":"publisher","first-page":"76","DOI":"10.3390\/diseases11020076","volume":"11","author":"M Savaliya","year":"2023","unstructured":"Savaliya M, Surati D, Surati R, Padmani S, Boussios S. Posterior reversible encephalopathy syndrome after Pazopanib therapy. Diseases. 2023;11:76. https:\/\/doi.org\/10.3390\/diseases11020076.","journal-title":"Diseases"},{"key":"1222_CR27","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1016\/j.clcc.2013.12.003","volume":"13","author":"ZW Myint","year":"2014","unstructured":"Myint ZW, Sen JM, Watts NL, Druzgal TJ, Nathan BR, Ward MD, et al. Reversible posterior leukoencephalopathy syndrome during Regorafenib treatment: a case report and literature review of reversible posterior leukoencephalopathy syndrome associated with multikinase inhibitors. Clin Colorectal Cancer. 2014;13:127\u201330. https:\/\/doi.org\/10.1016\/j.clcc.2013.12.003.","journal-title":"Clin Colorectal Cancer"},{"key":"1222_CR28","doi-asserted-by":"publisher","unstructured":"Aanes SG, Nieder C, Prytz J, Odeh F. En mann i 50-\u00e5rene med nevrologiske symptomer under kreftbehandling. Tidsskriftet [Internet]. 2018 [cited 2025 May 6]; https:\/\/doi.org\/10.4045\/tidsskr.18.0096.","DOI":"10.4045\/tidsskr.18.0096"},{"key":"1222_CR29","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.2169\/internalmedicine.9593-17","volume":"57","author":"Y Osawa","year":"2018","unstructured":"Osawa Y, Gozawa R, Koyama K, Nakayama T, Sagoh T, Sunaga H. Posterior reversible encephalopathy syndrome after Lenvatinib therapy in a patient with anaplastic thyroid carcinoma. Intern Med. 2018;57:1015\u20139. https:\/\/doi.org\/10.2169\/internalmedicine.9593-17.","journal-title":"Intern Med"},{"key":"1222_CR30","doi-asserted-by":"publisher","first-page":"33","DOI":"10.3390\/brainsci13010033","volume":"13","author":"Y-J Tseng","year":"2022","unstructured":"Tseng Y-J, Chen C-N, Hong R-L, Kung W-M, Huang AP-H. Posterior reversible encephalopathy syndrome after lenvatinib therapy in a patient with olfactory neuroblastoma. Brain Sci. 2022;13:33. https:\/\/doi.org\/10.3390\/brainsci13010033.","journal-title":"Brain Sci"},{"key":"1222_CR31","doi-asserted-by":"publisher","first-page":"e1605","DOI":"10.1002\/cnr2.1605","volume":"5","author":"M Abhishek","year":"2022","unstructured":"Abhishek M, Renuka A, Ujjwal A, Amit C, Vijay P, Vanita N, et al. Atypical posterior reversible encephalopathy syndrome associated with Lenvatinib therapy in a patient with metastatic thyroid cancer\u2014a case report. Cancer Rep. 2022;5:e1605. https:\/\/doi.org\/10.1002\/cnr2.1605.","journal-title":"Cancer Rep"},{"issue":"3","key":"1222_CR32","doi-asserted-by":"publisher","first-page":"e136900","DOI":"10.5812\/ijem-136900","volume":"21","author":"DC Buenaventura","year":"2023","unstructured":"Buenaventura DC, Vargas-Sierra H, Aristizabal-Henao N, Torres-Grajales JL, Aguilar-Londono C, Gutierrez-Restrepo J. Posterior reversible encephalopathy syndrome as an adverse effect of Lenvatinib in a patient with papillary thyroid carcinoma: a case report. Int J Endocrinol Metab. 2023;21(3):e136900. https:\/\/doi.org\/10.5812\/ijem-136900.","journal-title":"Int J Endocrinol Metab"},{"key":"1222_CR33","doi-asserted-by":"publisher","first-page":"1487009","DOI":"10.3389\/fphar.2025.1487009","volume":"16","author":"M Chen","year":"2025","unstructured":"Chen M, Shen J, Jia R, Chang M, Zhang J, Zheng J, et al. Case report: posterior reversible encephalopathy syndrome after Lenvatinib treatment for hepatocellular carcinoma. Front Pharmacol. 2025;16:1487009. https:\/\/doi.org\/10.3389\/fphar.2025.1487009.","journal-title":"Front Pharmacol"},{"key":"1222_CR34","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1007\/s11523-020-00738-6","volume":"15","author":"E Raschi","year":"2020","unstructured":"Raschi E, Gatti M, Gelsomino F, Ardizzoni A, Poluzzi E, De Ponti F. Lessons to be learnt from real-world studies on immune-related adverse events with checkpoint inhibitors: a clinical perspective from pharmacovigilance. Targ Oncol. 2020;15:449\u201366. https:\/\/doi.org\/10.1007\/s11523-020-00738-6.","journal-title":"Targ Oncol"},{"key":"1222_CR35","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1111\/pcn.13511","volume":"77","author":"M Fusaroli","year":"2023","unstructured":"Fusaroli M, Giunchi V, Battini V, Gringeri M, Rimondini R, Menchetti M, et al. Exploring the underlying mechanisms of drug-induced impulse control disorders: a pharmacovigilance\u2013pharmacodynamic study. Psychiatry Clin Neurosci. 2023;77:160\u20137. https:\/\/doi.org\/10.1111\/pcn.13511.","journal-title":"Psychiatry Clin Neurosci"},{"key":"1222_CR36","unstructured":"FAERS Quarterly Data Extract Files [Internet]. [cited 2025 Apr 15]. https:\/\/fis.fda.gov\/extensions\/FPD-QDE-FAERS\/FPD-QDE-FAERS.html. Accessed 15 Apr 2025."},{"key":"1222_CR37","unstructured":"ChEMBL-ChEMBL [Internet]. [cited 2025 Apr 15]. https:\/\/www.ebi.ac.uk\/. Accessed 15 Apr 2025."},{"key":"1222_CR38","doi-asserted-by":"publisher","unstructured":"Harding S. IUPHAR\/BPS Guide to Pharmacology Database Report-April 2024 [Internet]. Zenodo; 2024 Apr. https:\/\/doi.org\/10.5281\/ZENODO.11046804.","DOI":"10.5281\/ZENODO.11046804."},{"key":"1222_CR39","doi-asserted-by":"publisher","first-page":"1544","DOI":"10.1111\/bcp.13238","volume":"83","author":"E Patras De Campaigno","year":"2017","unstructured":"Patras De Campaigno E, Bondon\u2010Guitton E, Laurent G, Montastruc F, Montastruc J, Lapeyre\u2010Mestre M, et al. Identification of cellular targets involved in cardiac failure caused by PKI in oncology: an approach combining pharmacovigilance and pharmacodynamics. Br J Clin Pharmacol. 2017;83:1544\u201355. https:\/\/doi.org\/10.1111\/bcp.13238.","journal-title":"Br J Clin Pharmacol"},{"key":"1222_CR40","doi-asserted-by":"publisher","first-page":"1802472","DOI":"10.1183\/13993003.02472-2018","volume":"53","author":"L Cornet","year":"2019","unstructured":"Cornet L, Khouri C, Roustit M, Guignabert C, Chaumais M-C, Humbert M, et al. Pulmonary arterial hypertension associated with protein kinase inhibitors: a pharmacovigilance\u2013pharmacodynamic study. Eur Respir J. 2019;53:1802472. https:\/\/doi.org\/10.1183\/13993003.02472-2018.","journal-title":"Eur Respir J"},{"key":"1222_CR41","doi-asserted-by":"publisher","first-page":"2373","DOI":"10.1111\/bcp.13693","volume":"84","author":"J Mah\u00e9","year":"2018","unstructured":"Mah\u00e9 J, De Campaigno EP, Chen\u00e9 A, Montastruc J, Despas F, Jolliet P. Pleural adverse drugs reactions and protein kinase inhibitors: identification of suspicious targets by disproportionality analysis from VigiBase. Brit J Clin Pharma. 2018;84:2373\u201383. https:\/\/doi.org\/10.1111\/bcp.13693.","journal-title":"Brit J Clin Pharma"},{"key":"1222_CR42","doi-asserted-by":"publisher","first-page":"585","DOI":"10.1007\/s40264-024-01423-7","volume":"47","author":"M Fusaroli","year":"2024","unstructured":"Fusaroli M, Salvo F, Begaud B, AlShammari TM, Bate A, Battini V, et al. The reporting of a disproportionality analysis for drug safety signal detection using individual case safety reports in pharmacovigilance (READUS-PV): explanation and elaboration. Drug Saf. 2024;47:585\u201399. https:\/\/doi.org\/10.1007\/s40264-024-01423-7.","journal-title":"Drug Saf"},{"key":"1222_CR43","doi-asserted-by":"publisher","first-page":"575","DOI":"10.1007\/s40264-024-01421-9","volume":"47","author":"M Fusaroli","year":"2024","unstructured":"Fusaroli M, Salvo F, Begaud B, AlShammari TM, Bate A, Battini V, et al. The reporting of a disproportionality analysis for drug safety signal detection using individual case safety reports in pharmacovigilance (READUS-PV): development and statement. Drug Saf. 2024;47:575\u201384. https:\/\/doi.org\/10.1007\/s40264-024-01421-9.","journal-title":"Drug Saf"},{"key":"1222_CR44","unstructured":"Fusaroli M, Giunchi V. DiAna version 2.1.0. An open-source toolkit for disproportionality analysis and other pharmacovigilance investigations in the FAERS [Internet]. 2024. https:\/\/fusarolimichele.github.io\/DiAna_package\/."},{"key":"1222_CR45","unstructured":"MedDRA, Medical dictionary for regulatory activities [Internet]. [cited 2024 July 27]. https:\/\/www.meddra.org\/. Accessed 27 July 2024."},{"key":"1222_CR46","doi-asserted-by":"publisher","first-page":"1275","DOI":"10.1007\/s40264-024-01471-z","volume":"47","author":"M Fusaroli","year":"2024","unstructured":"Fusaroli M, Polizzi S, Menestrina L, Giunchi V, Pellegrini L, Raschi E, et al. Unveiling the burden of drug-induced impulsivity: a network analysis of the FDA Adverse Event Reporting System. Drug Saf. 2024;47:1275\u201392. https:\/\/doi.org\/10.1007\/s40264-024-01471-z.","journal-title":"Drug Saf"},{"key":"1222_CR47","doi-asserted-by":"publisher","first-page":"539","DOI":"10.1038\/clpt.2013.24","volume":"93","author":"R Harpaz","year":"2013","unstructured":"Harpaz R, DuMouchel W, LePendu P, Bauer-Mehren A, Ryan P, Shah NH. Performance of pharmacovigilance signal-detection algorithms for the FDA Adverse Event Reporting System. Clin Pharmacol Ther. 2013;93:539\u201346. https:\/\/doi.org\/10.1038\/clpt.2013.24.","journal-title":"Clin Pharmacol Ther"},{"key":"1222_CR48","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1177\/0962280211403604","volume":"22","author":"GN Nor\u00e9n","year":"2013","unstructured":"Nor\u00e9n GN, Hopstadius J, Bate A. Shrinkage observed-to-expected ratios for robust and transparent large-scale pattern discovery. Stat Methods Med Res. 2013;22:57\u201369. https:\/\/doi.org\/10.1177\/0962280211403604.","journal-title":"Stat Methods Med Res"},{"key":"1222_CR49","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1111\/bcp.15178","volume":"89","author":"W Alkabbani","year":"2023","unstructured":"Alkabbani W, Gamble J. Active\u2010comparator restricted disproportionality analysis for pharmacovigilance signal detection studies of chronic disease medications: an example using sodium\/glucose cotransporter 2 inhibitors. Br J Clin Pharmacol. 2023;89:431\u20139. https:\/\/doi.org\/10.1111\/bcp.15178.","journal-title":"Br J Clin Pharmacol"},{"key":"1222_CR50","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1007\/s11523-021-00817-2","volume":"16","author":"A Goldman","year":"2021","unstructured":"Goldman A, Bomze D, Dankner R, Fourey D, Boursi B, Arad M, et al. Cardiovascular toxicities of antiangiogenic tyrosine kinase inhibitors: a retrospective, pharmacovigilance study. Target Oncol. 2021;16:471\u201383. https:\/\/doi.org\/10.1007\/s11523-021-00817-2.","journal-title":"Target Oncol"},{"key":"1222_CR51","doi-asserted-by":"publisher","first-page":"100338","DOI":"10.1016\/j.esmoop.2021.100338","volume":"7","author":"P Vallerio","year":"2022","unstructured":"Vallerio P, Orenti A, Tosi F, Maistrello M, Palazzini M, Cingarlini S, et al. Major adverse cardiovascular events associated with VEGF-targeted anticancer tyrosine kinase inhibitors: a real-life study and proposed algorithm for proactive management. ESMO Open. 2022;7:100338. https:\/\/doi.org\/10.1016\/j.esmoop.2021.100338.","journal-title":"ESMO Open"},{"key":"1222_CR52","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1016\/S1470-2045(22)00793-8","volume":"24","author":"JE Brown","year":"2023","unstructured":"Brown JE, Royle K-L, Gregory W, Ralph C, Maraveyas A, Din O, et al. Temporary treatment cessation versus continuation of first-line tyrosine kinase inhibitor in patients with advanced clear cell renal cell carcinoma (STAR): an open-label, non-inferiority, randomised, controlled, phase 2\/3 trial. Lancet Oncol. 2023;24:213\u201327. https:\/\/doi.org\/10.1016\/S1470-2045(22)00793-8.","journal-title":"Lancet Oncol"},{"key":"1222_CR53","doi-asserted-by":"publisher","first-page":"101966","DOI":"10.1016\/j.ctrv.2020.101966","volume":"84","author":"S Fogli","year":"2020","unstructured":"Fogli S, Porta C, Del Re M, Crucitta S, Gianfilippo G, Danesi R, et al. Optimizing treatment of renal cell carcinoma with VEGFR-TKIs: a comparison of clinical pharmacology and drug-drug interactions of anti-angiogenic drugs. Cancer Treat Rev. 2020;84:101966. https:\/\/doi.org\/10.1016\/j.ctrv.2020.101966.","journal-title":"Cancer Treat Rev"},{"issue":"3","key":"1222_CR54","doi-asserted-by":"publisher","first-page":"e46","DOI":"10.1161\/hyp.0000000000000224","volume":"80","author":"JB Cohen","year":"2023","unstructured":"Cohen JB, Brown NJ, Brown S-A, Dent S, Van Dorst DCH, Herrmann SM, et al. Cancer therapy-related hypertension: a scientific statement from the American Heart Association. Hypertension. 2023;80(3):e46\u201357. https:\/\/doi.org\/10.1161\/hyp.0000000000000224.","journal-title":"Hypertension"},{"key":"1222_CR55","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1007\/s00204-024-03874-4","volume":"99","author":"Y-X Du","year":"2025","unstructured":"Du Y-X, Li X, Ji S-W, Niu N. Hypertension toxicity of VEGFR-TKIs in cancer treatment: incidence, mechanisms, and management strategies. Arch Toxicol. 2025;99:67\u201381. https:\/\/doi.org\/10.1007\/s00204-024-03874-4.","journal-title":"Arch Toxicol"},{"key":"1222_CR56","doi-asserted-by":"publisher","first-page":"773","DOI":"10.1016\/S0008-6363(98)00228-4","volume":"41","author":"A Bouloumi\u00e9","year":"1999","unstructured":"Bouloumi\u00e9 A. Vascular endothelial growth factor up-regulates nitric oxide synthase expression in endothelial cells. Cardiovasc Res. 1999;41:773\u201380. https:\/\/doi.org\/10.1016\/S0008-6363(98)00228-4.","journal-title":"Cardiovasc Res"},{"key":"1222_CR57","doi-asserted-by":"publisher","first-page":"101204","DOI":"10.1016\/j.xcrm.2023.101204","volume":"4","author":"V Subbiah","year":"2023","unstructured":"Subbiah V, Verstovsek S. Clinical development and management of adverse events associated with FGFR inhibitors. Cell Rep Med. 2023;4:101204. https:\/\/doi.org\/10.1016\/j.xcrm.2023.101204.","journal-title":"Cell Rep Med"},{"key":"1222_CR58","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1038\/s41582-020-00427-y","volume":"17","author":"I Cortese","year":"2021","unstructured":"Cortese I, Reich DS, Nath A. Progressive multifocal leukoencephalopathy and the spectrum of JC virus-related disease. Nat Rev Neurol. 2021;17:37\u201351. https:\/\/doi.org\/10.1038\/s41582-020-00427-y.","journal-title":"Nat Rev Neurol"},{"key":"1222_CR59","doi-asserted-by":"publisher","first-page":"1016377","DOI":"10.3389\/fneur.2022.1016377","volume":"13","author":"E Hatchwell","year":"2022","unstructured":"Hatchwell E, Smith EB, Jalilzadeh S, Bruno CD, Taoufik Y, Hendel-Chavez H, et al. Progressive multifocal leukoencephalopathy genetic risk variants for pharmacovigilance of immunosuppressant therapies. Front Neurol. 2022;13:1016377. https:\/\/doi.org\/10.3389\/fneur.2022.1016377.","journal-title":"Front Neurol"},{"key":"1222_CR60","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1016\/S1474-4422(25)00232-7","volume":"24","author":"JE Fugate","year":"2025","unstructured":"Fugate JE, Hawkes MA, Rabinstein AA. Posterior reversible encephalopathy syndrome: evolving insights in diagnosis, management, and outcomes. Lancet Neurol. 2025;24:789\u2013800. https:\/\/doi.org\/10.1016\/S1474-4422(25)00232-7.","journal-title":"Lancet Neurol"},{"key":"1222_CR61","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1016\/S1470-2045(09)70161-5","volume":"10","author":"KR Carson","year":"2009","unstructured":"Carson KR, Focosi D, Major EO, Petrini M, Richey EA, West DP, et al. Monoclonal antibody-associated progressive multifocal leucoencephalopathy in patients treated with rituximab, natalizumab, and efalizumab: a review from the research on adverse drug events and reports (RADAR) project. Lancet Oncol. 2009;10:816\u201324. https:\/\/doi.org\/10.1016\/S1470-2045(09)70161-5.","journal-title":"Lancet Oncol"},{"key":"1222_CR62","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s00228-009-0739-z","volume":"66","author":"C Piccinni","year":"2010","unstructured":"Piccinni C, Sacripanti C, Poluzzi E, Motola D, Magro L, Moretti U, et al. Stronger association of drug-induced progressive multifocal leukoencephalopathy (PML) with biological immunomodulating agents. Eur J Clin Pharmacol. 2010;66:199\u2013206. https:\/\/doi.org\/10.1007\/s00228-009-0739-z.","journal-title":"Eur J Clin Pharmacol"},{"key":"1222_CR63","doi-asserted-by":"publisher","first-page":"1216","DOI":"10.1002\/pds.3320","volume":"21","author":"N Schmedt","year":"2012","unstructured":"Schmedt N, Andersohn F, Garbe E. Signals of progressive multifocal leukoencephalopathy for immunosuppressants: a disproportionality analysis of spontaneous reports within the US Adverse Event Reporting System (AERS). Pharmacoepidemiol Drug. 2012;21:1216\u201320. https:\/\/doi.org\/10.1002\/pds.3320.","journal-title":"Pharmacoepidemiol Drug"},{"key":"1222_CR64","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1080\/14740338.2016.1198775","volume":"15","author":"DW Raisch","year":"2016","unstructured":"Raisch DW, Rafi JA, Chen C, Bennett CL. Detection of cases of progressive multifocal leukoencephalopathy associated with new biologicals and targeted cancer therapies from the FDA\u2019s adverse event reporting system. Expert Opin Drug Saf. 2016;15:1003\u201311. https:\/\/doi.org\/10.1080\/14740338.2016.1198775.","journal-title":"Expert Opin Drug Saf"},{"key":"1222_CR65","doi-asserted-by":"publisher","first-page":"1323057","DOI":"10.3389\/fdsfr.2023.1323057","volume":"3","author":"PM Cutroneo","year":"2024","unstructured":"Cutroneo PM, Sartori D, Tuccori M, Crisafulli S, Battini V, Carnovale C, et al. Conducting and interpreting disproportionality analyses derived from spontaneous reporting systems. Front Drug Saf Regul. 2024;3:1323057. https:\/\/doi.org\/10.3389\/fdsfr.2023.1323057.","journal-title":"Front Drug Saf Regul"},{"key":"1222_CR66","doi-asserted-by":"publisher","first-page":"113168","DOI":"10.1016\/j.bbr.2021.113168","volume":"404","author":"D Cepaityte","year":"2021","unstructured":"Cepaityte D, Siafis S, Papazisis G. Safety of antipsychotic drugs: a systematic review of disproportionality analysis studies. Behav Brain Res. 2021;404:113168. https:\/\/doi.org\/10.1016\/j.bbr.2021.113168.","journal-title":"Behav Brain Res"},{"key":"1222_CR67","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.jclinepi.2021.01.015","volume":"134","author":"C Khouri","year":"2021","unstructured":"Khouri C, Petit C, Tod M, Lepelley M, Revol B, Roustit M, et al. Adverse drug reaction risks obtained from meta-analyses and pharmacovigilance disproportionality analyses are correlated in most cases. J Clin Epidemiol. 2021;134:14\u201321. https:\/\/doi.org\/10.1016\/j.jclinepi.2021.01.015.","journal-title":"J Clin Epidemiol"}],"container-title":["Targeted Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-026-01222-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11523-026-01222-3","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11523-026-01222-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T08:54:55Z","timestamp":1780131295000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11523-026-01222-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5]]},"references-count":67,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,5]]}},"alternative-id":["1222"],"URL":"https:\/\/doi.org\/10.1007\/s11523-026-01222-3","relation":{},"ISSN":["1776-2596","1776-260X"],"issn-type":[{"value":"1776-2596","type":"print"},{"value":"1776-260X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5]]},"assertion":[{"value":"29 December 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Monia Donati, Chiara Cancellerini, Valentina Giunchi, Simone Rossi, Francesco Massari, Francesco Gelsomino, Elisabetta Poluzzi, and Emanuel Raschi declare that they have no conflicts of interest that might be relevant to the contents of this manuscript.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval, Consent to Participate, Consent to Publish"}},{"value":"The datasets generated and\/or analyzed during the current study are publicly available in the FDA Adverse Event Reporting System (FAERS) database (\n                      \n                      ). The algorithm for cleaning FAERS data is open-source at\u00a0\n                      \n                      , and the cleaned database is available on an OSF repository (\n                      \n                      ) and through the R package DiAna (\n                      \n                      ). The code generated and\/or analyzed in the current study is available from the corresponding author on reasonable request.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data Availability"}},{"value":"Not applicable.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code Availability"}},{"value":"Francesco Gelsomino and Emanuel Raschi contributed to the study conception. Monia Donati, Chiara Cancellerini, and Emanuel Raschi contributed to the study design.\u00a0Monia Donati and Chiara Cancellerini contributed to data collection. Valentina Giunchi performed the analysis. Monia Donati and Chiara Cancellerini drafted the manuscript. All authors contributed to the writing and editing of this paper. All authors contributed to interpreting the results and read and approved the final version submitted for publication.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author Contributions"}}]}}